4.8 Editorial Material

Smoking and the First Amendment

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 365, 期 25, 页码 2351-2353

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMp1113011

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Immunology

Antibiotic Development Incentives That Reflect Societal Value of Antibiotics

Helen W. Boucher, Thomas M. File, Vance G. Fowler, Amanda Jezek, John H. Rex, Kevin Outterson

CLINICAL INFECTIOUS DISEASES (2021)

Editorial Material Immunology

Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can... Now We Need to Start Pulling! COMMENT

John H. Rex, Kevin Outterson

CLINICAL INFECTIOUS DISEASES (2021)

Editorial Material Biotechnology & Applied Microbiology

Improving data sharing to increase the efficiency of antibiotic R&D

Wes Kim, Kevin Krause, Zak Zimmerman, Kevin Outterson

Summary: Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts' SPARK platform, plays a key role in this process.

NATURE REVIEWS DRUG DISCOVERY (2021)

Review Public, Environmental & Occupational Health

Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy

Claas Kirchhelle, Paul Atkinson, Alex Broom, Komatra Chuengsatiansup, Jorge Pinto Ferreira, Nicolas Fortane, Isabel Frost, Christoph Gradmann, Stephen Hinchliffe, Steven J. Hoffman, Javier Lezaun, Susan Nayiga, Kevin Outterson, Scott H. Podolsky, Stephanie Raymond, Adam P. Roberts, Andrew C. Singer, Anthony D. So, Luechai Sringernyuang, Elizabeth Tayler, Susan Rogers Van Katwyk, Clare I. R. Chandler

BMJ GLOBAL HEALTH (2020)

Editorial Material Public, Environmental & Occupational Health

Social, cultural and economic aspects of antimicrobial resistance

Timo Minssen, Kevin Outterson, Susan Rogers Van Katwyk, Pedro Henrique D. Batista, Clare I. R. Chandler, Francesco Ciabuschi, Stephan Harbarth, Aaron S. Kesselheim, Ramanan Laxminarayan, Kathleen Liddell, Michael T. Osterholm, Lance Price, Steven J. Hoffman

BULLETIN OF THE WORLD HEALTH ORGANIZATION (2020)

Article Public, Environmental & Occupational Health

A one health framework to estimate the cost of antimicrobial resistance

Chantal M. Morel, Richard A. Alm, Christine Ardal, Alessandra Bandera, Giacomo M. Bruno, Elena Carrara, Giorgio L. Colombo, Marlieke E. A. de Kraker, Sabiha Essack, Isabel Frost, Bruno Gonzalez-Zorn, Herman Goossens, Luca Guardabassi, Stephan Harbarth, Peter S. Jorgensen, Souha S. Kanj, Tomislav Kostyanev, Ramanan Laxminarayan, Finola Leonard, Gabriel Levy Hara, Marc Mendelson, Malgorzata Mikulska, Nico T. Mutters, Kevin Outterson, Jesus Rodriguez-Bano, Evelina Tacconelli, Luigia Scudeller

ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2020)

Article Public, Environmental & Occupational Health

The impact of infections on reimbursement in 92 US hospitals, 2015-2018

Laura Puzniak, Vikas Gupta, Kalvin C. Yu, Gang Ye, Kevin Outterson

Summary: The study compared the financial burden of hospital admissions for patients with and without infections, showing that infections led to a significant increase in medical time and costs, with only private insurance payers having a positive margin.

AMERICAN JOURNAL OF INFECTION CONTROL (2021)

Article Multidisciplinary Sciences

The effect of generic market entry on antibiotic prescriptions in the United States

Cecilia Kallberg, Jemma Hudson, Hege Salvesen Blix, Christine Ardal, Eili Klein, Morten Lindbaek, Kevin Outterson, John-Arne Rottingen, Ramanan Laxminarayan

Summary: The study found that one year after the entry of generics into the market, the number of prescriptions increased for five antibiotics (by 6% to 406%), while it decreased for one drug. These changes were sustained two years after.

NATURE COMMUNICATIONS (2021)

Article Oncology

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

Amila K. Nanayakkara, Helen W. Boucher, Vance G. Fowler, Amanda Jezek, Kevin Outterson, David E. Greenberg

Summary: Antibiotic resistance poses a significant threat to the success of cancer therapy, necessitating measures to control its emergence. Establishing a specialized monitoring system and finding better ways to predict, prevent, and treat antibiotic-resistant infections will have a positive impact on the care of cancer patients.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Article Immunology

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020

Kevin Outterson, Ebiowei S. F. Orubu, John Rex, Christine Ardal, Muhammad H. Zaman

Summary: Limited accessibility of new antibacterials in high-income countries challenges the assumption that these countries have complete access to all medicines. This study reveals that many high-income countries have limited patient access to new antibacterials, even after regulatory approval.

CLINICAL INFECTIOUS DISEASES (2022)

Article Economics

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?

Abigail R. Colson, Alec Morton, Christine Ardal, Kalipso Chalkidou, Sally C. Davies, Louis P. Garrison, Mark Jit, Ramanan Laxminarayan, Itamar Megiddo, Chantal Morel, Justice Nonvignon, Kevin Outterson, John H. Rex, Abdur Razzaque Sarker, Mark Sculpher, Beth Woods, Yue Xiao

Summary: Antimicrobial resistance poses a serious challenge to healthcare systems and has garnered increasing policy attention and funding for research and development. However, manufacturers are uncertain about the market demand for new antimicrobial technologies. Health technology assessment (HTA) needs to address deficiencies in appraising antimicrobial agents by adopting a problem-centric approach, developing tools for changing infection patterns, and incorporating epidemiological risks in their evaluation criteria. To be more effective, HTA agencies should expand their methodological toolkit, communicate their analysis to a wider audience, and consider both immediate health gains and long-term policy goals.

VALUE IN HEALTH (2021)

Article Health Care Sciences & Services

Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines

Kevin Outterson

Summary: This article discusses the commercial challenges faced by antibacterials, proposes policy initiatives for pull incentives, and estimates the global incentives required to create a functional market. The model indicates that strengthening pull incentives will have a positive impact on the global revenue stream for innovative antibacterials.

HEALTH AFFAIRS (2021)

News Item Biotechnology & Applied Microbiology

Trends in the global antibiotics market

Jacob Madden, Kevin Outterson

NATURE REVIEWS DRUG DISCOVERY (2023)

Editorial Material Economics

Global Pull Incentives for Better Antibacterials: The UK Leads the Way

Kevin Outterson, John H. Rex

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2023)

Article Ethics

A Pandemic Instrument Can Start Turning Collective Problems into Collective Solutions by Governing the Common-Pool Resource of Antimicrobial Effectiveness

Isaac Weldon, Kathy Liddell, Susan Rogers Van Katwyk, Steven J. Hoffman, Timo Minssen, Kevin Outterson, Stephanie Palmer, A. M. Viens, Jorge Vinuales

Summary: To address the challenge of global antimicrobial resistance, a pandemic treaty should include mechanisms for addressing access gap, conserving antimicrobials, financing new technologies, and establishing infection prevention measures. Lessons from biodiversity, climate, and nuclear governance can be applied.

JOURNAL OF LAW MEDICINE & ETHICS (2022)

暂无数据